News and Trends 4 Oct 2022Aeglea BioTherapeutics updates homocystinuria program Aeglea BioTherapeutics, Inc. says dosing in the third cohort of the phase 1/2 clinical trial of pegtarviliase for the treatment… October 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email